Earnings Release • Aug 14, 2015
Preview not available for this file type.
Download Source FileCompany announcement no 2015-10 14 August 2015
Revenue growth of 11% supported by successful product launches and exchange
rate movements
Free cash flow of DKK 543 million, equivalent to 21% growth
10% underlying EBIT growth – raising lower end of full-year EBIT guidance
William Demant Holding A/S today published its Interim Report 2015. Selected
highlights from the Interim Report are summarised below:
-- In the first half-year, the Group realised a revenue growth rate of 11%,
corresponding to revenue of DKK 5,043 million. All business activities
contributed positively to the Group’s growth.
-- Especially in the US, the Group benefitted from the successful introduction
in late February of the Oticon Inium Sense platform, with new products
launched across all styles, at all price points and in all markets. In our
US hearing aid wholesale activities, we saw 9% organic growth. The positive
impact was particularly apparent in the independent channel in the US,
where we enjoyed significant growth and market share gains.
-- Hearing Implants grew by 16% in local currencies, fuelled by double-digit
growth rates in bone-anchored hearing systems (BAHS) and also in cochlear
implants (CI).
-- The Group’s gross profit margin was reported at 74.2% supported by a
favourable development in the average selling price in the wholesale of
hearing aids.
-- Operating profit (EBIT) was reported at DKK 880 million, corresponding to
10% growth adjusted for earn-outs of DKK 36 million in the first half of
2014. The Group continues to generate a significant cash flow and thus
generated a free cash flow of DKK 543 million, corresponding to a 21%
increase on the first half of 2014.
-- We expect our operating profit (EBIT) for the second half of 2015 to be at
the same level or exceed the EBIT realised in the first half of the year.
Consequently, we now expect EBIT of DKK 1.8-2.0 billion for the full year
against a previous range of DKK 1.7-2.0 billion. The guidance provided does
not include any impact of the ongoing process to acquire Audika.
“I’m delighted by the successful, global launch of our full line of new
products based on the Oticon Inium Sense platform. This launch has led us to
take market shares in the first half-year, especially with the independent
dispensers in the US – a development that was also driven by a tremendous
effort by our US sales organisation,” says Niels Jacobsen, President & CEO of
William Demant Holding.
Mr Jacobsen continues: “It is also encouraging to see that all our efforts
convert into cash. In the first half-year, we delivered a free cash flow of 543
million kroner, corresponding to a growth rate of as much as 21%, which I find
highly satisfactory. Furthermore, we have now raised the lower end of our EBIT
guidance range for the full year, which is partly due to the strong, underlying
EBIT development we have seen so far this year.”
1st half 2015 1st half 2014 Change
Market conditions and business trends
In the first half-year of 2015, the global market for hearing aids developed in
line with the Group’s general expectations of 3-4% unit growth. After a strong
start to the year, market growth rates in North America softened a bit towards
the end of the period. The unit growth rate in North America was 9% in the
first half-year, with growth rates in both the private sector and VA of 9%. We
believe that in the period under review, unit growth in the major European
markets for hearing aids was flat, negatively impacted by a high growth rate in
Germany in the comparative half-year of 2014 due to changes to subsidy schemes.
Excluding Germany, the European market for hearing aids slightly exceeded our
full-year expectations of 3-4% unit growth.
It is estimated that the average selling price (ASP) on the global hearing aid
market is still under pressure, mainly due to mix shifts in channels, fiercer
competition and changes to public subsidy schemes. We estimate that the market
ASP was slightly negative in the first half-year and that in terms of value,
the global market for hearing aids has therefore seen flat to slightly positive
growth in the first half-year.
Hearing Devices
In the first half of 2015, our core business – the development, manufacture and
wholesale of hearing aids – generated organic revenue growth of 4%, thereby
exceeding the market growth rate. The launch of Oticon’s new Inium Sense
platform marked the biggest and broadest product launch ever undertaken by
Oticon. The platform was launched in all styles, at all price points and in all
markets in the course of only a few weeks, resulting in encouraging momentum in
the period under review.
In Europe, the Group’s sales were adversely affected by the negative growth
rates in Germany and the NHS in the UK. If we exclude sales in the German
market and sales to the NHS, the global, organic growth rate in the core
business was in the high single digits.
In North America, the Group’s wholesale business saw a strong sales upturn
after the introduction of the new Inium Sense platform. The positive impact of
the launch was particularly apparent in the independent channel in the US,
where we enjoyed significant growth and market share gains. The Group’s total
hearing aid wholesale activities in the US saw organic growth of 9% in the
first half of 2015. The changes we saw in market dynamics in the US in 2014
caused by one competitor’s decision to offer its premium brand to a big-box
retailer led to increased pricing pressure in 2014, especially with the
independent retailers. In our estimation, this higher ASP pressure in the
independent channel has stabilised in the US in the first half of 2015 compared
to the second half of 2014. However, due to the higher comparative figures our
hearing aid wholesale activities in the US saw a decline in the ASP in this
channel in the first half of 2015.
In the period under review, Hearing Devices, including the Group’s retail
activities, saw 3% organic growth. Our retail activities saw a satisfactory
increase in revenue driven by a combination of organic growth and acquisitions.
After a slow start to the year, especially in the US, our retail business
gradually picked up momentum in the period under review. The ongoing process of
consolidating our retail businesses in the US is pivotal in order for us to be
able to continue to grow and develop our business.
Diagnostic Instruments
In the first half of 2015, Diagnostic Instruments saw 3% growth in local
currencies and 2% organic growth in a market that has only shown modest growth.
After a slow start to the year, we succeeded in picking up momentum towards the
end of the first half-year, despite not having seen the effect of tenders in
terms of sales. This momentum has continued into the second half-year and with
the new product introductions and the expected impact from tenders, we believe
that we are well positioned to gain further market shares in 2015.
Hearing Implants
In the first half-year, Hearing Implants saw 16% growth in local currencies of
which the major part was organic growth. Both our bone-anchored hearing systems
(BAHS) and our cochlear implants (CI) business delivered double-digit growth
rates in the first half-year.
As far as our BAHS business is concerned, the increase in revenue was driven by
both existing markets and several new markets. However, the competition has
become fiercer, and the market for bone conduction solutions is very
fragmented: The new market for transcutaneous hearing solutions is expanding
steadily, which bodes well for our upcoming, active, transcutaneous product
concept. We believe that with a larger product offering targeted at patients
with conductive hearing loss and single-sided deafness, our BAHS business is in
a very good position to continue to take market shares in the future.
The CI business is growing in existing and new markets alike. In the first
half-year, we won a number of new, important tenders in some of the emerging
markets. The products in these tenders are however offered at lower prices,
resulting in a lower overall ASP. We are slowly, but steadily, getting access
to several European markets, and the wait-and-see approach by some clinics that
we are currently experiencing is likely to be less pronounced, when we launch
the new CI system later this year. With some delay, the new implant has now
been CE marked, which means that we will be able to start the introduction of
the new implant to the commercial market in the fourth quarter. In the first
half-year, costs have grown slightly more than sales in absolute numbers, but
we still expect to meet the plans made for the full year – however at the risk
of realising a proportion of sales in early 2016 instead of in late 2015.
As expected, the general expansion in especially R&D and distribution is a
significant cost driver, and Hearing Implants will therefore have a dilutive
effect on our Group's profitability in the short to medium term, however with
the strong potential of becoming accretive to profitability in the longer term.
Results for the first half of 2015
In the period under review, the Group realised 11% reported revenue growth,
corresponding to revenue of DKK 5,043 million. Growth in revenue in local
currencies was more than 3% and is attributable to organic and acquired growth
of almost 3 and 1 percentage points, respectively. Exchange rates had a
positive impact of 8 percentage points on revenue, which includes losses on
foreign exchange hedging activities of DKK 106 million realised in the first
half of 2015.
In the first half-year, consolidated gross profit totalled DKK 3,743 million,
corresponding to a 13% increase. The gross profit margin was 74.2%, or an
increase of 1.1 percentage points, which can mainly be attributed to the
wholesale of hearing aids and a combination of higher ASP and lower unit costs.
Furthermore, we have seen an increase in the sale of Group-manufactured hearing
aids to own retail compared to the sale of third-party instruments, which has
also had a positive impact on the Group’s gross profit margin.
In the period under review, capacity costs totalled DKK 2,891 million, or an
increase of 6% in local currencies compared with the same period last year,
including the impact of acquisitions.
Operating profit (EBIT) amounted to DKK 880 million in the first half-year,
corresponding to an underlying growth rate of 10%, adjusted for earn-outs of
DKK 36 million in the first half of 2014. Reported growth in EBIT of 6% was
mainly driven by Oticon and the successful launch of the Inium Sense platform.
Our ongoing optimisation of Group operations and our ongoing efforts to
establish one of the leading, global hearing implant businesses carried
additional costs in the period under review. The reported profit margin (EBIT
margin) was 17.4%, or a decrease of 1 percentage point on the same period last
year. When adjusting for exchange rates (both translation and transaction
effects) and earn-outs in the first half of 2014, the underlying EBIT margin
improved by nearly 2 percentage points compared to the same period last year.
In the first half of 2015, consolidated cash flows from operating activities
were DKK 755 million against DKK 706 million in the same period last year,
corresponding to an increase of 7%, which is mainly due to an increase in
operating profit (EBIT). The corresponding cash conversion ratio (CFFO/EBIT) of
86% was again very satisfactory and at the same high level as last year (85%).
Free cash flows (excluding the acquisition of enterprises, participating
interests and activities) totalled DKK 543 million against DKK 450 million in
the first half of 2014, which is equivalent to an increase of 21%.
Other matters
As of today, the Company has bought back a total of 692,511 shares worth DKK
367 million, bringing the total number of treasury shares to 556,912,
corresponding to 1% of the share capital. The Company cancelled 2,236,403
treasury shares at the most recent annual general meeting.
As previously announced, the Group has signed a share purchase agreement to
acquire a controlling interest in Audika Groupe, one of the leading networks of
hearing care providers in France, from the controlling shareholder Holton. If
successful, the purchase of a controlling interest will commit William Demant
to commence a mandatory public tender offer for the remaining 46.1% of the
share capital outstanding of Audika, which is listed on Euronext in Paris. The
entire transaction will amount to an equity value of EUR 168 million. The
acquisition of the controlling interest in Audika is subject to approval by the
French competition authority. Timewise, the mandatory public tender offer is
most likely to be launched in the second half of 2015.
Outlook for the 2015 financial year
In the second half of the year, we expect operating profit (EBIT) to be at the
same level or exceed the EBIT realised in the first half of 2015. Consequently,
we now expect EBIT of DKK 1.8-2.0 billion for the full year against the
previously announced range of DKK 1.7-2.0 billion. In view of the strengthened
exchange rates, we estimate the positive exchange rate impact on reported Group
revenue in 2015 to slightly exceed the previously announced level of 4-5%
including the impact of exchange rate hedging. The remaining part of the
initial guidance is repeated below and is still based on the assumptions of
market and business trends described in our Annual Report 2014:
“In 2015, we expect to generate growth in sales and earnings in the Group’s
three business activities: Hearing Devices, Diagnostic Instruments and Hearing
Implants.
As far as the hearing aid market is concerned, we expect to see unit growth of
3-4%, which will however be dented by a decline in the market’s average selling
price due to continued mix changes and fierce competition. In terms of value,
we expect to see flat to slightly positive market trends in 2015. The
anticipated growth in 2015 in our own hearing aid wholesale activities is based
on the solid momentum gained towards the end of 2014, which has continued into
2015 and has been further fuelled by Oticon’s major global product launch in
the first quarter of 2015. Oticon’s new products will from the very start be
globally available in all styles and at all price points.
In Diagnostic Instruments, we expect a continuation in 2015 of the sales
momentum we experienced in the second half of 2014 in a market that is expected
to grow by 2-4% in value.
In Hearing Implants, i.e. cochlear implants and bone-anchored hearing systems,
we expect to deliver double-digit growth rates in 2015 measured in value.
The appreciation of several of the Group’s invoicing currencies, most notably
the US dollar, is expected to have an estimated 4-5% positive impact on
reported Group revenue in 2015 based on exchange rates in early 2015 and
including the impact of exchange rate hedging. However, the resulting positive
exchange rate impact on the Group’s earnings will partly be offset by the
translation of the Group’s Swiss R&D cost base into Danish kroner. The full
positive impact on operating profit of the Group’s strengthened invoicing
currencies is postponed due to currency hedging.
Acquisitions made in 2014 and in 2015 up until today will impact revenue by
less than 1% in 2015. Our ongoing efforts to improve the Group’s efficiency
through the entire value chain will continue. We will thus build and implement
a new global ERP system, establish shared services for our back-office
functions, further centralise our ITE production and repair services and put
our new global distribution centre in Poland into operation. Also, our cost
base will continue to be impacted by our expansion in Hearing Implants,
especially driven by R&D and distribution activities. All these major
undertakings are meant to deliver value for the Group in the medium to long
term, but will in the short term, which means also in 2015, naturally have a
dilutive effect on the Group’s profitability, as it has also been the case in
recent years.
The guidance provided above does not include any impact of the outcome of the
current negotiations to acquire Audika.”
All in all, based on the Group’s results in the first half-year, the expected
revenue growth in the remaining part of 2015 and our continued efforts to
improve our efficiency and to build a future growth platform in Hearing
Implants, we are guiding for an operating profit (EBIT) for 2015 in the range
of DKK 1.8-2.0 billion (previously DKK 1.7-2.0 billion).
¨ ¨ ¨ ¨ ¨ ¨ ¨
Further information: Other contacts:
Niels Jacobsen, President & CEO Stefan Ingildsen, SVP Finance
Phone +45 3917 7300 Søren B. Andersson, VP IR
www.demant.com Rasmus Sørensen, IR Officer
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.